Founding Partner, BioTrack Capital
Kevin (Penghui) Chen is Managing Partner of Biotrack Capital. Prior to his current role, he was a partner at Sequoia Capital, responsible for healthcare investment. Before Sequoia Capital, Mr. Chen served as head and managing director of Everbright Healthcare. He led the investments in many leading healthcare companies in China including BGI, Amcare, Betta Pharmaceuticals Inc, JIDA Pharmaceuticals Inc, Yuwell Medical, Zai Lab, Medtrum Medical, STP, Bai Yang Pharmaceuticals, Forerunner Medical, Guahao. Before Everbright, he worked at ShangPharma, a leading China CRO company, first as COO & CFO from 2008 to 2010, and later as President in 2011. He took the company public at NYSE in 2010. Prior to ShangPharma, Mr. Chen was a vice president at CITIC Capital, responsible for the healthcare and consumer industry. Before CITIC Capital, he held executive positions at BD & Corporate Investment at fortune 500 companies. Mr. Chen also worked as a research scientist at Ligand Pharmaceuticals (Nasdaq: LGND) in San Diego, California.
Mr. Chen holds a bachelor’s degree in chemistry from Nanjing University, a master’s degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.